KNIGHT THERAPEUTICS INC (GUD.CA) Stock Analyst Ratings
Canada - TSX:GUD - CA4990531069 - Common Stock
6.13 CAD
+0.02 (+0.33%)
ChartMill assigns a Buy % Consensus number of 78% to GUD.CA. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.96. This target is 29.79% above the current price.
GUD.CA was analyzed by 11 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about GUD.CA.
In the previous month the buy percentage consensus was at a similar level.
GUD.CA was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-08-12 | Stifel Nicolaus Research | Upgrade | |
| 2022-08-12 | National Bank of Canada Financial | Upgrade | Outperform |
| 2022-03-28 | Bloom Burton | Initiate | Buy |
| 2022-03-26 | Bloom Burton | Downgrade | Buy -> Accumulate |
| 2022-03-25 | Raymond James Capital | Downgrade | Outperform |
| 2022-03-25 | National Bank of Canada Financial | Downgrade | Outperform |
| 2022-03-25 | Canaccord Capital | Upgrade | Buy |
| 2022-03-25 | National Bank Financial | Downgrade | Outperform |
| 2021-11-12 | RaymondJamesFinancial | Initiate | Outperform |
| 2021-11-12 | NationalBankFinancial | Upgrade | Outperform |
| 2021-09-24 | Raymond James Financial | Initiate | Outperform |
| 2021-08-17 | Raymond James Financial | Initiate | Outperform |
| 2021-07-13 | RBC Capital | Initiate | Outperform |
| 2021-05-17 | Raymond James Financial | Initiate | Outperform |
| 2021-04-26 | National Bank Financial | Upgrade | Outperform |
| 2021-04-26 | Raymond James Financial | Upgrade | Outperform |
| 2021-03-27 | Bloom Burton | Upgrade | Accumulate -> Buy |
| 2021-03-26 | Raymond James Financial | Initiate | Outperform |
KNIGHT THERAPEUTICS INC / GUD.CA FAQ
What do analysts expect the price target to be for KNIGHT THERAPEUTICS INC (GUD.CA)?
11 analysts have analysed GUD.CA and the average price target is 7.96 CAD. This implies a price increase of 29.79% is expected in the next year compared to the current price of 6.13.
How do analysts rate KNIGHT THERAPEUTICS INC (GUD.CA)?
The consensus rating for KNIGHT THERAPEUTICS INC (GUD.CA) is 78.1818 / 100 . This indicates that analysts generally have a positive outlook on the stock.